The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer

References

• Parikshak NN , Swarup V , Belgard TG , et al. Genome-wide changes in lncRNA, splicing, and regional gene expression patterns in autism. Nature . 2016;540(7633):423–427. doi:10.1038/nature20612 27919067
   PubMed Web of Science ®Google Scholar
• Kapranov P , Cheng J , Dike S , et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science . 2007;316(5830):1484–1488. doi:10.1126/science.1138341 17510325
   PubMed Web of Science ®Google Scholar
• Calore F , Lovat F , Garofalo M . Non-coding RNAs and cancer. Int J Mol Sci . 2013;14(8):17085–17110. doi:10.3390/ijms140817085 23965974
   PubMed Web of Science ®Google Scholar
• Engreitz JM , Haines JE , Perez EM , et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature . 2016;539(7629):452–455. doi:10.1038/nature20149 27783602
   PubMed Web of Science ®Google Scholar
• Lee JT . Epigenetic regulation by long noncoding RNAs. Science . 2012;338(6113):1435–1439. doi:10.1126/science.1231776 23239728
   PubMed Web of Science ®Google Scholar
• Jiang YZ , Liu YR , Xu XE , et al. Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value. Cancer Res . 2016;76(8):2105–2114. doi:10.1158/0008-5472.CAN-15-3284 26921339
   PubMed Web of Science ®Google Scholar
• Carey LA , Dees EC , Sawyer L , et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res . 2007;13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109 17438091
   PubMed Web of Science ®Google Scholar
• Dent R , Trudeau M , Pritchard KI , et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res . 2007;13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045 17671126
   PubMed Web of Science ®Google Scholar
• Tischkowitz M , Brunet J-S , Bégin LR , et al. Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancer . 2007;7:134. doi:10.1186/1471-2407-7-134 17650314
   PubMed Web of Science ®Google Scholar
• Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol . 2012;23(Suppl 6):vi7–12. doi:10.1093/annonc/mds187 23012306
   PubMed Web of Science ®Google Scholar
• Harris LN , Broadwater G , Lin NU , et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res . 2006;8(6):R66.17129383
   PubMed Web of Science ®Google Scholar
• Omarini C , Guaitoli G , Pipitone S , et al. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res . 2018;10:91–103. doi:10.2147/CMAR.S146658 29391830
   PubMed Web of Science ®Google Scholar
• Liu Q , Huang J , Zhou N , et al. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res . 2013;41(9):4976–4987. doi:10.1093/nar/gkt182 23558749
   PubMed Web of Science ®Google Scholar
• Pasic I , Shlien A , Durbin AD , et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res . 2010;70(1):160–171. doi:10.1158/0008-5472.CAN-09-1902 20048075
   PubMed Web of Science ®Google Scholar
• Cong M , Li J , Jing R , et al. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma. Tumour Biol . 2016;37(7):9441–9450. doi:10.1007/s13277-015-4414-y 26781978
   PubMedGoogle Scholar
• Qi P , Xu MD , Ni SJ , et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med . 2013;11:122. doi:10.1186/1479-5876-11-122 23680400
   PubMed Web of Science ®Google Scholar
• Ding YC , Yu W , Ma C , et al. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol . 2014;7(11):8065–8070.25550852
   PubMed Web of Science ®Google Scholar
• Soussi T , Ishioka C , Claustres M , et al. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer . 2006;6(1):83–90. doi:10.1038/nrc1783 16397528
   PubMed Web of Science ®Google Scholar
• Wapinski O , Chang HY . Long noncoding RNAs and human disease. Trends Cell Biol . 2011;21(6):354–361. doi:10.1016/j.tcb.2011.04.001 21550244
   PubMed Web of Science ®Google Scholar
• Hsu DS , Balakumaran BS , Acharya CR . Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol . 2007;25(28):4350–4357. doi:10.1200/JCO.2007.11.0593 17906199
   PubMed Web of Science ®Google Scholar
• Yardley DA , Coleman R , Conte P , et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol . 2018;29(8):1763–1770. doi:10.1093/annonc/mdy201 29878040
   PubMed Web of Science ®Google Scholar
• Rinn JL , Kertesz M , Wang JK , et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell . 2007;129(7):1311–1323. doi:10.1016/j.cell.2007.05.022 17604720
   PubMed Web of Science ®Google Scholar
• Chu C , Qu K , Zhong FL , et al. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell . 2011;44(4):667–678. doi:10.1016/j.molcel.2011.08.027 21963238
   PubMed Web of Science ®Google Scholar
• Berezikov E , van Tetering G , Verheul M , et al. Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. Genome Res . 2006;16(10):1289–1298. doi:10.1101/gr.5159906 16954537
   PubMed Web of Science ®Google Scholar
• Dolganiuc A , Petrasek J , Kodys K , et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res . 2009;33(10):1704–1710. doi:10.1111/j.1530-0277.2009.01007.x 19572984
   PubMed Web of Science ®Google Scholar
• Niu Y , Mo D , Qin L , et al. Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-alpha gene expression by modulating Sp1. Immunology . 2011;133(1):8–20. doi:10.1111/j.1365-2567.2010.03374.x 21320120
   PubMed Web of Science ®Google Scholar
• Kruse JP , Gu W . Modes of p53 regulation. Cell . 2009;137(4):609–622. doi:10.1016/j.cell.2009.04.050 19450511
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER , Lowe SW . Putting p53 in context. Cell . 2017;170(6):1062–1078. doi:10.1016/j.cell.2017.08.028 28886379
   PubMed Web of Science ®Google Scholar
• He L , He X , Lim LP , et al. A microRNA component of the p53 tumour suppressor network. Nature . 2007;447(7148):1130–1134. doi:10.1038/nature05939 17554337
   PubMed Web of Science ®Google Scholar
• Qi P , Xu M-D , Shen X-H , et al. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. Int J Cancer . 2015;137(6):1269–1278. doi:10.1002/ijc.29516 25765901
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N , Marciano E , Meiri E , et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell . 2007;26(5):731–743. doi:10.1016/j.molcel.2007.05.017 17540598
   PubMed Web of Science ®Google Scholar
• Hung T , Wang Y , Lin MF , et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet . 2011;43(7):621–629. doi:10.1038/ng.848 21642992
   PubMed Web of Science ®Google Scholar
• Baugh EH , Ke H , Levine AJ , et al. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ . 2018;25(1):154–160. doi:10.1038/cdd.2017.180 29099487
   PubMed Web of Science ®Google Scholar
• Peluso I , Yarla NS , Ambra R , Pastore G , Perry G . MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents. Semin Cancer Biol . 2017;56:185–195. doi:10.1016/j.semcancer.2017.09.002 28912082
   PubMed Web of Science ®Google Scholar
• Matsuda S , Ichimura M , Ogino M , et al. Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (review). Int J Oncol . 2016;49(5):1785–1790. doi:10.3892/ijo.2016.3710 27826621
   PubMed Web of Science ®Google Scholar